Harvard research findings: The weight loss drug Ozempic is associated with rare vision loss

On July 3rd, Jin10.com reported that the analysis of doctors from Massachusetts Eye and Ear, a hospital affiliated with Harvard University, showed that Novo Nordisk’s popular weight-loss drugs Ozempic and Wegovy appear to be associated with an increased risk of rare vision loss. Research on medical records showed that compared to those who used other brand-name weight-loss drugs, patients who used Novo Nordisk’s weight-loss drugs to lose weight were seven times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION).